Velti, VELT, Profile, Summary

Featured Companies

Velti | VELT | Profile | Summary


 

Velti, VELT, is a mobile marketing provider founded over 13 years ago, it develops and executes highly interactive campaigns. Velti was among the first companies to initiate, develop, and deliver advertising and marketing initiatives across the mobile channel. Today Velti's leading global marketing platform, connecting brands with consumers around the world.

 

The company delivers technology and services that enable companies to engage with and reach their consumers through innovative mobile marketing and advertising efforts. The mGage platform is available for agencies and companies ready for a set of self-service based tools that consolidate media management, simplify mobile asset production, and deliver highly engaging messaging campaigns. For those who want professional assistance in achieving mobile goals, Velti's managed services organization offers expert help in developing strategies, programs, and hosting services to support mobile initiatives.
 

The Velti team now has a global footprint in 15+ countries, supporting Fortune 500 companies around the world. Over the years, Velti has extended its global leadership position through the strategic acquisition of companies whose technologies offer synergies to the mGage platform. In 2010, Velti acquired Media Cannon, a developer of mobile advertising tools and technology, and Mobclix, a mobile ad exchange network. In 2011, Velti acquired Mobile Interactive Group (MIG), the UK's largest mobile marketing company, and also Air2Web, a leading provider of mobile customer relationship management (mCRM) solutions for consumer brands in the United States and India. As of January 2012, Velti completed its acquisition of CASEE, the largest mobile advertising exchange in China.

 

The mGage®
Mobile Marketing Platform

Velti's mGage empowers brands to use mobile to transform their business. Whether it's ad delivery and measurement, cross-channel messaging campaigns, or mobile site development, our secure and scalable platform allows marketers to execute highly personalized, enterprise mobile marketing campaigns.

Velti makes it simple for you to capture the full revenue potential of your mobile ad inventory. A single SDK lets you work with as many ad networks as you like, giving you complete flexibility and control over the ads you run.

 

Sources: Velti , OxBridge Research, Daily Stock Deals, Penny Stock Monster.
 

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney

we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

 

Teryl Resources,TRC.V/TRYLF, Profile

Featured Companies

 

  

Teryl Resources | TRC.V/TRYLF | Profile

 

Teryl Resources Corp., - TRC.V / TRYLF – has several gold prospects near the Kinross Gold Corp's Fort Knox Mine in Alaska, a silver/lead/zinc prospect adjacent to Silvercorp's (SVM) mine in British Columbia, and Oil & Gas wells in Texas.

 

Teryl has a 10% net profit interest in the Stepovich claims. A 100% interest in the Westridge property and a 50% interest in the Fish Creek property, adjacent to the Gil property. Teryl sold its 20% interest in the Gil property in Fairbanks, Alaska, to Fairbanks Gold Mining Corp., a wholly owned subsidiary of Kinross Gold Corp. (KCG), for $15 million dollars plus a ½ of 1% royalty for the life of the mine.

 

Teryl owns a 30% working interest and a 10% NPI interest in the Silverknife property, a silver/lead/zinc prospect located in Northern B.C. adjacent to Silvercorp's silver/lead/zinc discovery.

 

Teryl also has an interest in three producing oil and gas wells in Texas, these wells are operated by Anadarko Petroleum.

 

 

 

Fish Creek property

 

Teryl Resources has commenced a placer and hard rock diamond drilling program on the Fish Creek property in the Fairbanks, Alaska mining district.

 

Teryl's consulting geologist, Paul D. Gray, P.Geo. will oversee the drilling program, core logging , and assay protocols on behalf of the Company. The operator of the drill will be Kenn Roberts of Texas, and Pete Rutledge, project manager.

 

Kenn Roberts, a First Nations from Yukon has multiple years of drilling experience in remote locations and has served as mineral development advisor to First Nations.

 

Teryl owns a 50% interest in the Fish Creek property, Keltic Bryce owns a 50% working interest and Linux Gold Corp. (LNXGF) retains a 5% royalty interest in Teryl's interest.

 

The Fish Creek property consists of 30 claims adjacent to the Gil property, currently owned by Kinross Gold Corporation. The Gil 20% interest, previously owned by Teryl Resources Corp., was acquired by Kinross for $15 million dollars.


 

Westridge Property

 

A geological report on the Westridge gold property has been prepared by David Adams, B.S., M.S., CPG. Teryl has appointed Pete Rutledge, Geologist, as an independent contractor to evaluate the Westridge property.

 

The Westridge property is located approximately 16 km north of Fairbanks, Alaska. The property consists of 48 State of Alaska mining claims controlled by Teryl Resources Corp.

 

The claims cover approximately 1,749 acres on the north flank of the main ridge between Pedro Creek and upper Dome Creek; both of these drainages were significant historic placer gold producers. Access to the property is excellent: the Elliott Highway transects the westernmost edge of the property, and the Silver Fox Mine road transects the southwest portion of the property.

  

All claim holdings comprising the property are in good standing, and no encumbrances to future mining activities are known or anticipated.

 

 

SILVERKNIFE PROPERTY OWNERSHIP:

 

» Teryl Resources Corp. owns 30% working

interest and has a 10% Net Profit Interest

(“NPI”)

 

» Minewest Silver & Gold owns 70% subject to

the 10% NPI held by Teryl

 

The Silverknife Property

(Mineral Claims consisting of 1,594 Acres)

 

A proposed Phase I exploration program consisting of a desk study followed by a series of on-the-ground Property boundary and drill collar location surveys, followed by geophysics and diamond drilling with a

recommended budget of $358,700 is recommended for the Silverknife Property.

 

The exploration programs (and budgets), presented herein, are designed to identify the accurate location of the mineral titles

boundary with respect to historic drill collars and test the Silverknife Property’s precious and base metal mineral potential and will yield enough information to guide Minewest and Teryl subsequent mineral

exploration programs on the Property. Samples have been collected to confirm the assay results, however, due to the inclement weather conditions, the Phase I exploration program has been delayed.

 

 

Sources: Teryl Resources Corp., Kinross Gold Corp., Linux Gold Corp., SilverCorp.

 

 

 

 

 

Forward-looking statements:- The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements, including those described in the Company's Financial Statements, Management Discussion and Analysis and Material Change Reports filed with the Canadian Securities Administrators and available at www.sedar.com, and the Company's 20-F annual report filed with the United States Securities and Exchange Commission at www.sec.gov.

This profile/research report/email letter/blog/posting in forums/social-media/t/f does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities of the Company have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclosure/Disclaimer:- OxBridge Research publishes sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by OxBridge and/or its affiliates.OxBridge Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment of up to five thousand dollars in compensation from the company/a third party/shareholder. We receive compensation from companies for providing various IR services, including publication, advertisement,and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer, if you need assistance contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it

OxbridgeResearch.com, All Rights Reserved. Trademarks/logos are of their respective owners.

It's YOUR money - Invest WISELY TM

Last Updated - Tuesday, 25 June 2013
 

Best Picks, Top Gainers from Friday, 06/21/2013

Recent Alerts

 

NLST SNTA CYTK IBIO OXBT ZGNX STP CSUN IMMU MBIS
3.17% 12.47% 22.03% 8.37% 14.05% 2.50% 5.63% 6.74% 16.24% 2.98%
tmxmone tmxmone tmxmone tmxmone tmxmone tmxmone tmxmone tmxmone tmxmone tmxmone

Best Performers, Top Picks, Double Digit Gainers from Friday 06/21/2013
source: Daily Stock Deals

Last Updated - Saturday, 22 June 2013
 

Anavex Life Sciences, AVXL, Profile, Summary

Featured Companies

Anavex Life Sciences |AVXL | Profile

Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. The Anavex portfolio comprises novel, wholly owned sigma receptor agonists and antagonists. The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose (SAD) clinical trial. The company has also started scale-up manufacturing for ANAVEX 1-41, its second lead compound, targeting depression and AD. With sufficient quantities of ANAVEX 1-41 in hand, the company will be in a position to advance the program and begin preclinical studies on large animals in the near term.

Neurological diseases (CNS): Anavex SIGMACEPTOR™-N program involves the discovery and development of original drug candidates, targeting neurological diseases such as Alzheimer’s disease, epilepsy, and depression. The company’s lead drug candidates exhibit high affinity and selectivity to sigma receptors and also synergistic action with other receptors, such as Muscarinic and NMDA, with strong evidence of anti-amnesic, neuroprotective, and anxiolytic properties.

Oncology: Anavex SIGMACEPTOR™-C program involves the discovery and development of original drug candidates targeting cancer. The company’s lead drug candidates exhibit high affinity to sigma receptors with strong evidence for selective apoptosis of cancerous cells, without affecting healthy cells, anti-metastatic and low toxicity properties in various types of cancer such as melanoma, prostate and pancreas, and neuropathic pain.

In addition, several series of sigma ligands currently at different stages of development, target stroke, diabetes, multiple sclerosis and Parkinson’s disease.


 

The Pipe Line

Anavex’s lead drug candidate ANAVEX 2-73 -targeting Alzheimer’s Disease- is in Phase 1 clinical trials. The company has also initiated scale-up manufacturing of ANAVEX 1-41 targeting a range of important CNS disorders, including depression and Alzheimer’s Disease. Three more of its compounds (for malignant melanoma, prostatic cancer and epilepsy) are expected to reach final preclinical stages in the near term.

Other early-stage preclinical research (see diagram) involves drug candidates that target diseases like depression, neuropathic pain and various types of cancer.

Source: Anavex, OxBridge Research, Daily Stock Deals

 

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Last Updated - Friday, 07 June 2013
 
Page 6 of 54
Penny Stock Monster
Sound View Plaza, 7th Floor
1266 E Main St.
Stamford, CT 06902, US
FREE! Premium Membership. DON'T miss the next Exclusive Alert! Become
a MEMBER Today!

Look for exclusive alerts

The Score Card

ARTI.PK* 0.0021   + 52%
EHSK.PK 0.17   + 108%
HGSI 3.35   + 226%
INCC.OB 0.01   + 346%
JGPK.OB 0.18   + 116%
STZU.PK 0.12   + 41%
TTEG.OB 0.36   + 156%

 

Look us up ON
these and other
PREMIER FINANCIALweb sites.
FREE! Premium Membership. DON'T miss the next Exclusive Alert! Become a MEMBER Today!